Angel Pharmaceuticals

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
ITKSmall molecule
Atopic DermatitisNon-Hodgkin Lymphoma
Peripheral T-Cell Lymphoma
MupadolimabNo recent activity
Phase 1
CD73Monoclonal antibody
Non-Small Cell Lung Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
June 2027 (1)
soquelitinibPhase 2Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Eczema, Atopic
Est. primary completion 2027-06 · NCT07441395 · CT.gov ↗
What to watch
November 2027 (1)
soquelitinibPhase 3Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma …
Est. primary completion 2027-11 · NCT06561048 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 January 2025Topline resultsoquelitinibInterim Phase 1 data from Cohorts 1 and 2 in atopic dermatitis

Financial reports

No financial reports recorded.